Astellas Sees Further FDA Action On Prograf MR In Early 2008
This article was originally published in PharmAsia News
Executive Summary
Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1
You may also be interested in...
Schering-Plough Pulls Garenoxacin Application In Europe
Action comes one year after the company withdrew an NDA for the antibiotic in the U.S.
Death Reported In Phase II Trial For Astellas/FibroGen’s Oral EPO Candidate
Announcement comes just ahead of an FDA advisory committee meeting to discuss EPO products.
Astellas’ Prograf “Approvable” For Use In Combination With Roche’s CellCept
Firm will meet with FDA to get combination therapy for prevention of kidney transplant rejection approved.